Verastem, Inc.
General ticker "VSTM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $591.9M (TTM average)
Verastem, Inc. does not follow the US Stock Market performance with the rate: -17.9%.
Estimated limits based on current volatility of 3.8%: low 5.55$, high 5.99$
Factors to consider:
- Total employees count: 73 (+28.1%) as of 2023
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Commercialization delays, Capital shortage, Intellectual property risks
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.01$, 13.53$]
- 2026-12-31 to 2027-12-31 estimated range: [3.89$, 11.01$]
Financial Metrics affecting the VSTM estimates:
- Positive: with PPE of -2.5 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0.21 <= 0.74
- Positive: 19.19 < Shareholder equity ratio, % of 23.21 <= 42.57
- Negative: Investing cash flow per share per price, % of -1.77 <= -0.60
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term VSTM quotes
Long-term VSTM plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $10.00MM | $30.91MM |
| Operating Expenses | $92.08MM | $124.96MM | $201.04MM |
| Operating Income | $-92.08MM | $-114.96MM | $-170.13MM |
| Non-Operating Income | $4.72MM | $-15.50MM | $-39.34MM |
| Interest Expense | $4.14MM | $4.56MM | $1.14MM |
| R&D Expense | $61.36MM | $81.33MM | $114.60MM |
| Income(Loss) | $-87.37MM | $-130.45MM | $-209.47MM |
| Taxes | $0.00MM | $0.18MM | $0.00MM |
| Net Income(Loss)* | $-87.37MM | $-130.64MM | $-209.47MM |
| Stockholders Equity | $57.37MM | $-28.89MM | $57.20MM |
| Inventory | $0.00MM | $0.00MM | $1.83MM |
| Assets | $149.72MM | $101.54MM | $246.44MM |
| Operating Cash Flow | $-86.46MM | $-104.77MM | $-137.51MM |
| Capital expenditure | $0.00MM | $0.03MM | $0.00MM |
| Investing Cash Flow | $-44.45MM | $59.97MM | $-9.62MM |
| Financing Cash Flow | $134.19MM | $54.78MM | $263.31MM |
| Earnings Per Share** | $-3.96 | $-3.66 | $-3.02 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.